関連する実験動画

Updated: Jan 13, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

ルキソリチニブは、口腔ケラチノサイトにおけるインターフェロン-γ誘導性JAK/STAT活性化を抑制する

Kim N Stolte¹, Anna Fedorova¹, Sameh Attia¹

¹Department of Periodontology, Oral Medicine and Oral Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Berlin, Germany.

Clinical and experimental dental research

|January 10, 2026

要旨

Objectives:

The Janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway plays a crucial role in oral inflammatory diseases such as oral lichen planus (OLP) and periodontitis. Interferon-gamma (IFN-γ) is a cytokine that activates the JAK/STAT pathway. This study aimed to evaluate the effect of the JAK1/2 inhibitor ruxolitinib on IFN-γ-driven inflammation in oral keratinocytes.

Material And Methods:

Human oral keratinocytes (OKG4) were stimulated with 10 ng/mL IFN-γ to assess the expression and phosphorylation status of JAK1, JAK2, STAT1, STAT2, and human leukocyte antigen (HLA)-DRB1. Ruxolitinib (1 µM) was used to inhibit IFN-γ-induced signaling. Analyses were performed using Western blotting, immunofluorescence microscopy, and cell viability assays.

Results:

IFN-γ significantly upregulated pSTAT1 at 30 min (control: 1.00 ± 0.00, IFN-γ: 29.17 ± 9.26, p = 0.0013), with sustained activation after 24 h (IFN-γ: 29.49 ± 18.26, p = 0.0127). HLA-DRB1 expression was also increased (control: 1.00 ± 0.00, IFN-γ: 3.51 ± 1.28, p = 0.0127). Co-treatment with IFN-γ and ruxolitinib reduced both pSTAT1 (p = 0.3448) and HLA-DRB1 (p = 0.3448) expression to baseline levels. Ruxolitinib had no effect on cell viability (p > 0.9999).

Conclusions:

IFN-γ induces robust and sustained activation of STAT1 and upregulation of HLA-DRB1 in oral keratinocytes, both effectively suppressed by ruxolitinib. These findings underscore the therapeutic potential of targeting the JAK/STAT pathway in oral inflammatory diseases.

キーワード:

ヤヌスキナーゼ阻害剤ヤヌスキナーゼインターフェロンガンマ扁平苔癬口腔

さらに関連する動画

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production

Published on: March 2, 2014

関連する概念動画

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...